Clinicians Discuss Balancing Platelet Counts and Quality of Life in ITP Case

When clinicians evaluated a patient case involving chronic immune thrombocytopenia, initial treatment selections split evenly across three distinct therapies, yet symptom persistence ultimately forced a shift in clinical strategy.

Physicians Split on Initial Chronic Immune Thrombocytopenia Therapies

Polling participants on initial therapy for a patient with chronic immune thrombocytopenia yielded an identical three-way split of 33.3% for eltrombopag (Promacta), rituximab (Rituxan), and rilzabrutinib (Wayrilz). Mehta noted that all three choices were defensible. Eltrombopag is a thrombopoietin receptor agonist that directly targets low platelet counts, rituximab provides a finite dosing course to spare younger patients years of daily medication, and rilzabrutinib is an oral, reversible Bruton tyrosine kinase inhibitor that pairs platelet activity with fatigue reduction benefits observed in key trials.

The patient initially started on eltrombopag at 50 mg daily. Although her platelet count improved to 62 × 10⁹/L, heavy menstrual bleeding and fatigue persisted, with her FACIT-Fatigue score moving only from 23 to 27 while she remained unable to run. She reported an inability to get through a full workweek and asked about discontinuing therapy.

Symptom Persistence Versus Laboratory Thresholds

Subsequent platelet counts fluctuated between 18 and 38 × 10⁹/L before dropping to 19 × 10⁹/L alongside ongoing heavy menstrual bleeding, a hemoglobin level of 9.1 g/dL, and a FACIT-Fatigue score of 21, leading to the discontinuation of eltrombopag after the patient declined a splenectomy. Meng Zhao, MD, of Providence-Swedish Cancer Institute, questioned whether treatment should be driven by fatigue alone if platelet counts sit safely above 30 × 10⁹/L. Mehta responded that his clinical approach has evolved to allow escalation as a defined trial of two to four months when fatigue significantly impacts a patient’s life, continuing the escalation only if raising the platelet count further successfully relieves the symptom.

Heavy menstrual bleeding complicated the clinical picture further. Mehta observed that premenopausal women with chronic immune thrombocytopenia may experience significant menorrhagia even when platelet counts appear adequate on paper at 40 to 50 × 10⁹/L, requiring iron deficiency from chronic blood loss to be ruled out before fatigue is blamed solely on the condition. Ashok Bapat, MD, of Sutter Santa Rosa, cautioned that premenopausal patients presenting with new or worsening heavy bleeding also require a workup for endometrial cancer or fibroids. Mehta added a prescribing caution regarding patients on thrombopoietin receptor agonists who consider estrogen-containing oral contraceptives for bleeding control, noting that combining the two compounds compounds the thrombotic risk already carried by the receptor agonist therapy alone.

Following eltrombopag discontinuation, polling preferences shifted decisively toward rilzabrutinib at 53.8%, followed by rituximab at 23.1%, with a clinical trial referral and fostamatinib (Tavalisse) drawing smaller shares. Examining findings from the phase 3 ADVANCE IV trial (NCT04188379), Mehta discussed efgartigimod (Vyvgart)—a neonatal Fc receptor antagonist that decreases circulating IgG autoantibodies—noting it delivered sustained platelet responses in 22% of chronic patients against 5% for placebo (P = .032), alongside meaningful quality-of-life gains seen in an open-label extension. Meanwhile, evaluation of the phase 3 VAYHIT2 trial (NCT05653219) for ianalumab (VAY736)—a B-cell activating factor receptor antibody combined with eltrombopag following the failure of first-line corticosteroids—revealed that the 9-mg/kg dose more than doubled 6-month stable response rates compared with placebo plus eltrombopag (62% vs 39%, P = .045), while additionally enhancing fatigue scores across both the PROMIS-Fatigue and ITP-PAQ-Fatigue instruments. Neither agent has received FDA approval for immune thrombocytopenia.

Participants noted how the roundtable reshaped their perspectives on managing patient quality of life. Pritam Tayshete, MD, of Virginia Mason Franciscan Health, stated that prior focus centered primarily on platelet counts rather than fatigue, but the presented studies changed what he will examine in detail going forward. Christopher DiSimone, MD, of Eisenhower Health, highlighted that patients insured through plans like school district coverages often face coverage guidelines built around outdated frameworks, making it difficult to treat beyond strict platelet control even when clinical circumstances demand it.